Phreesia (NYSE:PHR) Director Lisa Egbuonu-Davis Sells 2,546 Shares

Phreesia, Inc. (NYSE:PHR) Director Lisa Egbuonu-Davis sold 2,546 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $9.53, for a total transaction of $24,263.38. Following the transaction, the director owned 38,316 shares in the company, valued at approximately $365,151.48. The trade was a 6.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Phreesia Price Performance

Phreesia stock opened at $9.96 on Friday. Phreesia, Inc. has a 1 year low of $7.77 and a 1 year high of $32.76. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a 50 day moving average price of $9.35 and a 200 day moving average price of $11.99. The company has a market cap of $615.94 million, a price-to-earnings ratio of 66.43 and a beta of 0.91.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Wednesday, May 27th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $130.94 million for the quarter, compared to the consensus estimate of $130.08 million. Phreesia had a net margin of 1.85% and a return on equity of 5.13%. Phreesia’s revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.07) earnings per share. Sell-side analysts predict that Phreesia, Inc. will post 0.35 earnings per share for the current year.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Phreesia by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock worth $134,177,000 after acquiring an additional 437,462 shares in the last quarter. Greenhouse Funds LLLP grew its position in Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after acquiring an additional 557,265 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Phreesia in the fourth quarter valued at approximately $1,203,000. Tudor Investment Corp ET AL purchased a new stake in shares of Phreesia during the third quarter valued at approximately $4,173,000. Finally, King Luther Capital Management Corp raised its stake in shares of Phreesia by 172.6% during the fourth quarter. King Luther Capital Management Corp now owns 268,314 shares of the company’s stock valued at $4,540,000 after purchasing an additional 169,900 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analysts are still viewing Phreesia as a “Hold,” suggesting the stock’s long-term outlook is not being broadly written off by Wall Street. Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of “Hold” by Brokerages
• Neutral Sentiment: A director, Lisa Egbuonu-Davis, sold 2,546 shares in a pre-arranged Rule 10b5-1 transaction. While insider sales can attract attention, the filing indicates it was scheduled in advance rather than a discretionary move. Director stock sale disclosure
• Negative Sentiment: Phreesia is facing repeated investor alerts from law firms about a securities fraud class action, which may keep pressure on the stock until the deadline passes and more clarity emerges. Phreesia investigation alert
• Negative Sentiment: Several firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, The Gross Law Firm, the Schall Law Firm, and DJS Law Group, are urging investors to participate in the class action before the July 13 deadline, reinforcing the legal risk narrative. Phreesia sued for securities law violations

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PHR shares. Wells Fargo & Company reissued an “equal weight” rating and set a $9.00 price target (down from $15.00) on shares of Phreesia in a research report on Wednesday, May 20th. KeyCorp cut their price objective on Phreesia from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. Barclays reaffirmed an “equal weight” rating and issued a $10.00 price objective (down from $24.00) on shares of Phreesia in a research note on Thursday, May 14th. Truist Financial increased their target price on shares of Phreesia from $11.00 to $12.00 and gave the stock a “hold” rating in a research report on Thursday, May 28th. Finally, Needham & Company LLC reduced their price target on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Nine equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $16.65.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.